1. Headline & intro
Silicon Valley has mostly framed brain–computer interfaces as a race to put more metal into more brains. Max Hodak’s Science Corp is quietly betting on the opposite: less metal, more biology. According to reporting by TechCrunch, the company is preparing to place its first sensor in a human brain — the first step toward a future implant that mixes lab‑grown neurons with electronics. That sounds like sci‑fi, but it’s actually a sharp strategic pivot for the entire BCI field. In this piece, we’ll look at what’s really new here, why the regulatory path is controversial, and how this could reshape both medicine and the human‑augmentation narrative.
2. The news in brief
As reported by TechCrunch, Science Corporation — founded in 2021 by former Neuralink president and co‑founder Max Hodak — is preparing for its first U.S. human study of a brain sensor.
Yale neurosurgery chair Dr. Murat Günel has joined as scientific adviser to lead early clinical work. The initial human trial will not yet include the lab‑grown neurons Science ultimately wants to use. Instead, surgeons would place a tiny sensor containing 520 recording electrodes, about the size of a pea, on top of the brain, inside the skull but outside brain tissue.
Science plans to enroll patients who already require major brain surgery, such as some stroke cases where a section of the skull must be removed to relieve pressure. During those procedures, the company hopes to place its device on the cortex to record activity and test safety.
According to TechCrunch, Science does not intend to seek formal FDA approval for this early work, arguing risk is minimal because the device doesn’t penetrate brain tissue. The company recently raised a $230 million Series C at a $1.5 billion valuation and is already advancing its PRIMA retinal implant for blindness, with broader European availability targeted once regulators sign off.
3. Why this matters
Most BCI headlines focus on spectacular demos — a paralyzed person moving a cursor, for example. Science’s approach matters for a quieter, more fundamental reason: it’s trying to fix the biggest structural weakness of current invasive BCIs.
Today’s leading implants, including Neuralink’s, rely on metal electrodes implanted into brain tissue. They work, sometimes astonishingly well, but they cause damage simply by being there. Tissue scarring and micro‑motion around the probes tend to degrade signal quality over time. That’s fine for a lab demo, less fine if you’re promising an interface that lasts decades.
Science is betting that a “biohybrid” layer — electronics plus living neurons that integrate with the patient’s own brain cells — could offer a gentler, longer‑lived connection. If that works, the upside is huge: more stable signals, better stimulation, and potentially a platform that scales beyond rare, severe disabilities.
There’s also a business reality. The current BCI market for conditions like ALS or high‑spinal cord injuries is both medically vital and commercially small. A platform that can address common disorders — Parkinson’s, epilepsy, stroke recovery, chronic pain — or even elective enhancement, unlocks a much larger opportunity.
The losers, if Science’s thesis holds, are companies locked into deep, penetrating electrodes as their core architecture. The winners could include not just Science, but hospitals and device makers that prefer a lower‑risk implant that sits on the brain rather than in it.
However, Science’s decision to proceed without full FDA approval for the first implants is a double‑edged sword. It may accelerate learning and reduce cost, but it also raises questions about where the line should be between “adjunct” experimental hardware during surgery and a de facto human trial of a BCI platform. How regulators respond will shape the next decade of neurotech.
4. The bigger picture
Science Corp is entering a field that has suddenly become crowded. Neuralink has already implanted its first human device and publicly demonstrated cursor control. Synchron is taking a different surgical route with its stent‑like electrode system placed via blood vessels, aiming for a less invasive but also lower‑bandwidth interface. Academic groups have decades of experience with Utah arrays and ECoG grids.
Within that landscape, Science’s move sits at the convergence of three trends:
- From proof‑of‑concept to longevity. Early BCIs proved that decoding intent from neurons is possible. The next competitive front is durability: devices that last years without repeated surgeries. Biohybrid designs are one attempt to solve that.
- From pure electronics to living systems. Biotech is moving toward “electroceuticals” and cell therapies; neurotech is naturally following. Pairing lab‑grown cells with precise stimulation echoes what’s happening in Parkinson’s research, where cell replacement and deep brain stimulation are being explored in parallel.
- From assistive to augmentative. Once you can safely read and write neural activity at scale, the line between therapy (restoring lost function) and enhancement (adding new capabilities) blurs. Hodak has been explicit about that long‑term ambition.
There is historical precedent. Cochlear implants and deep brain stimulation for Parkinson’s started as highly controversial surgeries; today they are standard for selected patients. But they’re still relatively crude: metal electrodes, bulk hardware, and limited channel counts.
If Science can show that an epidural, neuron‑friendly interface delivers rich signals and precise stimulation without damaging tissue, it could set the template for the “second generation” of BCIs — devices designed from day one to coexist with the brain for decades. That would matter as much for incumbents like Medtronic and Abbott as for headline‑grabbing startups.
5. The European angle
For European readers, this story is not just about a Silicon Valley founder’s next act. It highlights a strategic question: will Europe be primarily a market for American neurotech, or a co‑shaper of the rules and technologies themselves?
Science’s most advanced product, the PRIMA retinal implant for macular‑related blindness, was originally developed by a European research effort and is now being pushed toward wider EU use. That means the first large‑scale commercial success of the company may actually land on European soil, under the EU’s Medical Device Regulation (MDR), not under the FDA.
That matters because Europe has a very different regulatory and cultural stance. Under GDPR, brain data is almost certainly “special category” personal data, requiring strict safeguards. The Digital Services Act and forthcoming AI Act will influence how any AI models trained on neural data can be used, shared, and commercialised.
European health systems and payers will also be more demanding on proven clinical benefit and cost‑effectiveness than early‑adopter U.S. markets. An implant that promises sci‑fi enhancements but doesn’t clearly beat existing treatments on real‑world outcomes will struggle to get reimbursed in Germany, France or the Nordics.
On the other hand, Europe has a deep neuromodulation and brain‑imaging research base, from German and Swiss epilepsy centers to Scandinavian stroke‑rehab programs. If Science wants to run serious, long‑term clinical studies, it is likely to need European hospitals as partners — and that gives EU regulators and ethics boards real leverage to shape how biohybrid BCIs evolve.
6. Looking ahead
The sensor Science wants to place on human brains in the near term is really a scouting mission. The main technical questions now are:
- Can an epidural, high‑density sensor record stable, high‑quality signals over months to years?
- Does the extra hardware meaningfully increase surgical risk for already‑vulnerable patients?
- How useful is the data for concrete clinical tasks: seizure prediction, mapping function, guiding stimulation?
The truly radical phase — adding lab‑grown neurons to create a biological bridge — is still years away. Growing cells that are safe, consistent and compatible with each individual’s immune system is non‑trivial. Getting those cells to wire up in the “right” way, and then decoding or steering that activity, is even harder.
TechCrunch cites 2027 as an optimistic date to start formal trials. Realistically, we are probably looking at a decade before a biohybrid BCI could reach anything like routine clinical use, and longer before any credible consumer‑grade “brain upgrade” emerges.
In the meantime, watch for three signals:
- Regulatory pushback or acceptance of Science’s no‑FDA early implants in the U.S., and how European regulators respond if similar studies are proposed.
- Partnerships with major hospitals and device companies — a sign that incumbents take the biohybrid approach seriously.
- Clear, quantified clinical wins in areas like Parkinson’s, stroke rehab or epilepsy monitoring. Without those, the field risks sliding into another hype cycle like the early 2010s brain‑training boom.
7. The bottom line
Science Corp’s plan to place its first sensor on a human brain is less about catching up to Neuralink and more about trying to leapfrog the entire invasive‑electrode paradigm. The biohybrid bet is scientifically ambitious and ethically fraught, but if it works, it could define what “long‑term” brain–computer interfaces look like.
For European and global readers alike, the key question is no longer whether we will put computers into closer dialogue with our brains, but who sets the terms — on safety, data, enhancement and access. That’s a conversation technologists, clinicians, regulators and citizens need to join now, not when the first consumer “extra sense” implant goes on sale.
